Vermillion Completes Name Change From Ciphergen Biosystems, Inc.
Published: Aug 27, 2007
FREMONT, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Vermillion, Inc. today announced that it has completed its previously announced name change from Ciphergen Biosystems, Inc. . Today at market open, the trading symbol for Vermillion's common stock on the NASDAQ Capital Market will change to VRML.
"Our new name reflects health, life and passion, as well as our commitment to becoming a leading provider of high-value diagnostics tests that help physicians diagnose, select appropriate treatments and improve outcomes for patients," said Gail S. Page, President and CEO of Vermillion, Inc.
No change of stockholder certificates is required and all current certificates in the name of Ciphergen Biosystems will remain valid for future transfers.
About Vermillion, Inc.
Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology/hematology, cardiology and women's health with an initial focus in ovarian cancer. Based in Fremont, California, more information about Vermillion can be found on the Web at http://www.vermillion.com.
This press release contains "forward-looking" statements regarding Vermillion (formerly Ciphergen), including statements with respect to the anticipated closing of the private placement. Any statements contained in this press release that are not historical facts may be deemed to be forward- looking statements. The words "will," "expected," "intends" or similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Vermillion's results to differ materially from those indicated by these forward- looking statements, including risks associated with the satisfaction of the conditions to the closing of the private placement, as well as other risks detailed from time to time in Vermillion's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. Vermillion does not undertake any obligation to update forward-looking statements. You are encouraged to read Vermillion's reports filed with the U.S. Securities and Exchange Commission, available at http://www.sec.gov.Vermillion, Inc.
CONTACT: Sue Carruthers, Investor Relations of Vermillion, Inc.,+1-510-505-2233; or Daryl Messinger of WeissComm Partners, +1-415-946-1062
Web site: http://www.vermillion.com/